Cover Image
市場調查報告書

全球癌症生物標記市場

Global Cancer Biomarkers Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 260034
出版日期 內容資訊 英文 89 Pages
訂單完成後即時交付
價格
Back to Top
全球癌症生物標記市場 Global Cancer Biomarkers Market 2015-2019
出版日期: 2015年01月14日 內容資訊: 英文 89 Pages
簡介

全球癌症生物標記市場預計從2014年到2019年以18.26%的年複合成長率擴大。

本報告提供全球癌症生物標記市場相關調查、癌症的發病率與盛行率、癌症的診斷所使用的FDA已核准生物標記、市場規模的變化與預測、各地區的詳細分析、市場的各種影響因素分析、競爭環境與以及主要企業的簡介等彙整。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 發病率和盛行率

第8章 癌症的診斷所採用的生物標記

FDA核准完畢生物標記

第9章 蛋白質為基礎的癌症生物標記的FDA核准流程

第10章 各地區市場

第11章 購買標準

第12章 市場成長因素

第13章 成長因素與其影響

第14章 市場課題

第15章 成長因素與課題的影響

第16章 市場趨勢

第17章 趨勢與其影響

第18章 供應商環境

  • 競爭模式
    • 主要消息
    • M&A
  • 供應商分析
  • 其他卓越供應商

第19章 主要供應商分析

  • Abbott Laboratories
  • Affymetrix
  • Illumina
  • Qiagen
  • Quest Diagnostics
  • Roche Diagnostics
    • 主要資料
    • 產業概要
    • 各產業部門收益
    • 各地區收益
    • 產業策略
    • 主要的發展趨勢
    • SWOT分析等

第20章 相關報告

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR5058

About Cancer Biomarkers

Biomarkers are molecules present in the blood, other body fluids such as serum, urine, or in tissue that are indicators of a disease or abnormal conditions. Biomarkers are mostly used as diagnostic tools. Biomarkers help in identifying potential drug failures in initial stages, leading to savings in time and costs. Biomarkers are becoming an essential part of the drug discovery process. Cancer Biomarkers are proteins or metabolites indicative of tumor state and progression characteristics. They are non-invasive, enable high speed cancer diagnosis and also enhance early cancer detection and screening. The best example of a cancer biomarker is that of prostate specific antigen. PSA is measured in the blood to screen for and monitor treatment for prostate cancer. PSA, as a biomarker helps the doctors to monitor the progress of the cancer. It also helps to evaluate the response of the cancer to the treatment therapy.

TechNavio's analysts forecast the Global Cancer Biomarkers market to grow at a CAGR of 18.26 percent over the period 2014-2019.

Covered in this Report

TechNavio's report, Global Cancer Biomarkers Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Cancer Biomarkers market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Abbott Laboratories
  • Affymetrix
  • Illumina
  • Qiagen
  • Quest Diagnostics
  • Roche Diagnostics

Other Prominent Vendors

  • Agendia
  • Agilent Technologies
  • Alere
  • Ambry Genetics
  • Amgen
  • Astellas Pharma US
  • Astex Pharmaceuticals
  • Atossa Genetics
  • Beckman Coulter
  • Becton, Dickinson and Company
  • Biocurex
  • bioMerieux
  • Celldex Therapeutics
  • Clarient
  • diaDexus
  • DiagnoCure
  • Epigenomics
  • EUSA Pharma
  • Exact Sciences
  • Foundation Medicine
  • Fujirebio Diagnostics
  • Genomic Health
  • Geron
  • Immunomedics
  • Morphotek
  • Myriad Genetics
  • Nodality
  • Northwest Biotherapeutics
  • Ocimum Biosolutions
  • Oncothyreon
  • OriGene
  • Polymedco
  • Radient Pharmaceuticals
  • Randox Laboratories
  • Siemens Healthcare
  • US Biomarkers
  • Vermillion

Market Driver

  • Increased Prevalence of Cancer
  • For a full, detailed list, view our report

Market Challenge

  • Regulatory and Reimbursement Issues
  • For a full, detailed list, view our report

Market Trend

  • Growing Popularity of Companion Diagnostics
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Incidence and Prevalence

08. Biomarkers Used in Cancer Diagnosis

    • 08.1.1. Cancer Biomarkers : FDA Approved till 2012
    • 08.1.2. Cancer Biomarkers : FDA Approved 2013

09. FDA Approval Process for Protein-Based Cancer Biomarkers

10. Geographical Segmentation

  • 10.1. Cancer Biomarkers Market in the Americas
    • 10.1.1. Market Size and Forecast
    • 10.1.2. Cancer Biomarkers Market in US
  • 10.2. Cancer Biomarkers Market in the EMEA Region
    • 10.2.1. Market Size and Forecast
  • 10.3. Cancer Biomarkers Market in APAC Region
    • 10.3.1. Market Size and Forecast

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions
  • 18.2. Vendor Analysis 2014
  • 18.3. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. Abbott Laboratories
    • 19.1.1. Key Facts
    • 19.1.2. Business Description
    • 19.1.3. Business Segmentation
    • 19.1.4. Business Strategy
    • 19.1.5. Revenue by Business Segmentation
    • 19.1.6. Revenue Comparison 2011 and 2012
    • 19.1.7. Revenue by Geographical Segmentation
    • 19.1.8. Key Information
    • 19.1.9. SWOT Analysis
  • 19.2. Affymetrix
    • 19.2.1. Key Facts
    • 19.2.2. Business Overview
    • 19.2.3. Business Segmentation
    • 19.2.4. Business Segmentation by Revenue 2013
    • 19.2.5. Business Segmentation by Revenue 2012 and 2013
    • 19.2.6. Sales by Geography
    • 19.2.7. Business Strategy
    • 19.2.8. Key Information
    • 19.2.9. SWOT Analysis
  • 19.3. Illumina
    • 19.3.1. Key Facts
    • 19.3.2. Business Overview
    • 19.3.3. Business Segmentation
    • 19.3.4. Geographical Segmentation by Revenue 2013
    • 19.3.5. Business Strategy
    • 19.3.6. Key Information
    • 19.3.7. SWOT Analysis
  • 19.4. Qiagen
    • 19.4.1. Key Facts
    • 19.4.2. Business Overview
    • 19.4.3. Product Segmentation by Revenue 2013
    • 19.4.4. Product Segmentation by Revenue 2012 and 2013
    • 19.4.5. Geographical Segmentation by Revenue 2013
    • 19.4.6. Business Strategy
    • 19.4.7. Recent Developments
    • 19.4.8. SWOT Analysis
  • 19.5. Quest Diagnostics
    • 19.5.1. Key Facts
    • 19.5.2. Business Overview
    • 19.5.3. Business Segmentation by Revenue 2013
    • 19.5.4. Business Segmentation by Revenue 2011-2013
    • 19.5.5. Geographical Segmentation by Revenue 2013
    • 19.5.6. Business Strategy
    • 19.5.7. Recent Developments
    • 19.5.8. SWOT Analysis
  • 19.6. Roche Diagnostics
    • 19.6.1. Key Facts
    • 19.6.2. Business Overview
    • 19.6.3. Business Segmentation by Revenue 2013
    • 19.6.4. Geographical Segmentation by Revenue 2013
    • 19.6.5. Business Strategy
    • 19.6.6. Key Developments
    • 19.6.7. SWOT Analysis

20. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Cancer Biomarkers Market 2014-2019 (US$ billion)
  • Exhibit 3: Incidence of Various Types of Cancer in 2012
  • Exhibit 4: FDA Classification of Medical Devices by Type of Class
  • Exhibit 5: Global Cancer Biomarkers Market by Geographical Segmentation 2014
  • Exhibit 6: Global Cancer Biomarkers Market by Geographical Segmentation 2019
  • Exhibit 7: Cancer Biomarkers Market in the Americas 2014-2019 (US$ billion)
  • Exhibit 8: Cancer Biomarkers Market in US 2014-2019 (US$ billion)
  • Exhibit 9: Cancer Biomarkers Market in the EMEA Region 2014-2019 (US$ billion)
  • Exhibit 10: Cancer Biomarkers Market in the APAC Region 2014-2019 (US$ billion)
  • Exhibit 11: Global Cancer Biomarkers Market by Geographical Segmentation 2014-2019
  • Exhibit 12: Abbott Laboratories Inc.: Business Segmentation
  • Exhibit 13: Abbott Laboratories Inc.: Revenue by Business Segmentation 2012
  • Exhibit 14: Abbott Laboratories Inc.: Revenue by Business Segmentation 2011 and 2012 (US$ million)
  • Exhibit 15: Abbott Laboratories Inc.: Revenue by Geographical Segmentation 2012
  • Exhibit 16: Affymetrix Inc.: Business Segmentation 2013
  • Exhibit 17: Affymetrix Inc.: Business Segmentation by Revenue 2013
  • Exhibit 18: Affymetrix Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 19: Affymetrix Inc.: Sales by Geography 2013
  • Exhibit 20: Illumina: Business Segmentation
  • Exhibit 21: Illumina: Geographical Segmentation by Revenue 2013
  • Exhibit 22: Qiagen: Product Segmentation by Revenue 2013
  • Exhibit 23: Qiagen: Product Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 24: Qiagen: Geographical Segmentation by Revenue 2013
  • Exhibit 25: Global Cancer Biomarkers Market: Business Segmentation by Revenue 2013
  • Exhibit 26: Global Cancer Biomarkers Market: Business Segmentation by Revenue 2011-2013 (US$ billion)
  • Exhibit 27: Global Cancer Biomarkers Market: Geographical Segmentation by Revenue 2013
  • Exhibit 28: Roche Diagnostics: Business Segmentation by Revenue 2013
  • Exhibit 29: Roche Diagnostics: Geographical Segmentation by Revenue 2013
Back to Top